Amylin based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! Eloralintide, a selective amylin receptor agonist Everyone and their mother is talking about eloralintide, the new amylin receptor agonist showing up to 20% body weight reduction in early trials. Gabriel Alizaidy, MD, MS PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Eloralintide vs #Cagrilintide Eloralintide vs #Cagrilintide Which #Amylin Agonist is Better? YouTube PDF) Eloralintide, a selective, longacting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept